Abstract
The excess production of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in patients with acromegaly is associated with a range of complications which have important effects on quality of life and which lead to reduced life expectancy. The increased mortality of the disorder has been recognized in 18 studies, totaling 4,806 individuals with acromegaly and including 1,116 deaths during follow-up, with meta-analyses indicating a standardized mortality estimate of 1.7 (95% CI 1.5–2). Univariate and multivariate analyses within the individual studies have identified the presence of hypertension, diabetes, and cardiac disease as important predictors of survival, as well as estimated duration from onset of the condition to date of effective treatment. However, the most important impact on survival comes from reduction of circulating GH and IGF-I concentrations, with serum GH measured by radioimmunoassay of <2.5 μg/L and a serum IGF-I measurement within the normal range for age providing mortality estimates indistinguishable from the general population. The major comorbidities of acromegaly, including cardiovascular disease, stroke, diabetes, hypertension, arthropathy, and sleep apnea syndrome, also benefit from biochemical remission following treatment, and management of these complications of the disorder appears to be important in maintaining quality of life as well as assisting with reduction in mortality.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94:1509–17.
Strasburger CJ. Consensus statement. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and The Pituitary Society. J Clin Endocrinol Metab. 2004;89:3099–102.
Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999;2:29–41.
Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89:667–74.
Clayton RN. Cardiovascular function in acromegaly. Endocr Rev. 2003;24:272–7.
Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly:epidemiology, pathogenesis, and management. Endocr Rev. 2004;25:102–52.
Paisley AN, Izzard AS, Gemmell I, et al. Small vessel remodelling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly. J Clin Endocrinol Metab. 2009;94:1111–7.
Schiavon F, Maffei P, Martini C, et al. Morphologic study of microcirculation in acromegaly by capillaroscopy. J Clin Endocrinol Metab. 1999;84:3151–5.
Nikkila EA, Pelkonen R. Serum lipids in acromegaly. Metabolism. 1975;24:829–38.
Nabarro JD. Acromegaly. Clin Endocrinol. 1987;26:481–512.
Holdaway IM, Rajasoorya CR, Gamble GD, et al. Long-term treatment outcome in acromegaly. Growth Horm IGF Res. 2003;13:185–92.
Gouya H, Vignaux O, Le Roux P, et al. Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence. Am J Roentgenol. 2008;190:1576–82.
Pivonello P, Galderisi M, Auriemma RS, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and function. J Clin Endocrinol Metab. 2007;92:476–82.
Bogazzi F, Battolla L, Spinelli C, et al. Risk factors for development of coronary heart disease in patients with acromegaly: a 5-year prospective study. J Clin Endocrinol Metab. 2007;92:4271–7.
Cannavo S, Almoto B, Cavalli G, et al. Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab. 2006;91:3766–72.
Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994;15:555–73.
Pereira AM, Van Thiel SW, Lindner JR, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab. 2004;89:71–5.
Van der Klaauw AA, Bax JJ, Roelfsema F, et al. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res. 2006;16:101–7.
Colao A, Marek J, Goth MI, et al. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J Clin Endocrinol Metab. 2008;93:2243–8.
Fatti LM, Scacchi M, Lavezzi E, et al. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol. 2006;65:626–30.
Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004;89:1613–7.
Sherlock M, Reulen RC, Aragon Alonso A, et al. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab. 2009;94:4216–23.
Resmini E, Minuto F, Colao A, et al. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetes. 2009;46:85–95.
Coculescu M, Niculescu D, Lichiardopol R, et al. Insulin resistance and insulin secretion in non-diabetic acromegalic patients. Exp Clin Endocrinol Metab. 2007;115:308–16.
Jaffrain-Rea ML, Moroni C, Baldelli R, et al. Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol. 2001;54:189–95.
Mercado M, Gonzalez B, Sandoval C, et al. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. J Clin Endocrinol Metab. 2008;93:3411–5.
Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol. 1994;41:95–102.
Arita K, Kurisu K, Tominaga A, et al. Mortality in 154 surgically treated patients with acromegaly – a 10-year follow-up survey. Endocr J. 2003;50:163–72.
Puder JJ, Nilavar S, Post KD, et al. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab. 2005;90:1972–8.
Hodish I, Barkan A. Long-term effects of pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab. 2008;4:324–32.
Bex M, Abs R, T’Sjoen G, et al. AcroBel – the Belgian registry on acromegaly: a survey of the “real-life” outcome on 418 acromegalic subjects. Eur J Endocrinol. 2007;157:399–409.
Biermasz NR, Pereira AM, Smit JWA, et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab. 2005;90:2731–9.
Dons RF, Rosselet P, Pastakia B, et al. Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Clin Endocrinol. 1988;28:515–24.
Maffei P, Schiavon F, Ragazzi R, et al. Shoulder arthropathy in acromegaly. Abstracts of the 85th annual meeting US endocrinol society. 2003. p. P1–639.
Mazziotti G, Bianchi A, Bonadonna S, et al. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab. 2008;93:4649–55.
Colao A, Cannavo S, Marzullo P, et al. Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol. 2003;148:31–8.
Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: an analysis of individual patient data from 12 prospective studies. Ann Int Med. 2008;149:461–71.
Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–53.
Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998;83:2730–4.
Renehan A, Bhaskar P, Painter JE, et al. The prevalence and characteristics of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab. 2000;85:3417–24.
Bengtsson B-A, Eden S, Ernest I, et al. Epidemiology and long-term survival in acromegaly. Acta Med Scand. 1988;223:327–35.
Jones A. Radiation oncogenesis in relation to the treatment of pituitary tumours. Clin Endocrinol. 1991;35:379–97.
Rokkas T, Pistiolas D, Sechopoulos P, et al. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol. 2008;14:3484–9.
Van Haute FRB, Taboada GF, Correa LL, et al. Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging. Eur J Endocrinol. 2008;158:459–65.
Sze L, Schmid C, Bloch KE, et al. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol. 2007;156:321–9.
Wright AD, Hill DM, Lowy C, et al. Mortality in acromegaly. Q J Med. 1970;39:1–16.
Bates AS, Van’t Hoff W, Jones JM, et al. An audit of outcome of treatment in acromegaly. Q J Med. 1993;86:293–9.
Levy MJ, Matharu MS, Meeran K, et al. The clinical characteristics of headache in patients with pituitary tumours. Brain. 2005;128:1921–30.
Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151:439–46.
Beauregard C, Truong U, Hardy J, et al. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol. 2003;58:86–91.
Trepp R, Stettler C, Zwahlen M, et al. Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien). 2005;147:243–51.
Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab. 2005;90:4081–6.
Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol. 1980;12:71–9.
Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2008;93:61–7.
Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89–95.
Bengtsson BA, Jonsson B, Nilsson B. Increased mortality in acromegaly is mainly caused by cardiovascular diseases. Abstracts of the 81st annual scientific meeting US endocrine society. 1999. p. P3–648.
Etxabe J, Gaztambide S, Latorre P, et al. Acromegaly: an epidemiological study. J Endocrinol Invest. 1993;16:181–7.
Abosch A, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab. 1998;83:3411–8.
Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab. 2004;89:2789–96.
Shimatsu A, Yokogoshi Y, Saito S, et al. Long-term survival and cardiovascular complications in patients with acromegaly and pituitary gigantism. J Endocrinol Invest. 1998;21:55–7.
Swearingen B, Barker FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83:3419–26.
Holdaway IM. Excess mortality in acromegaly. Horm Res. 2007;68 Suppl 5:166–72.
Sherlock M, Aragon Alonso A, Reulen RC, et al. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clin Endocrinol. 2009;71:74–81.
Freda PU. Monitoring of acromegaly: what should be performed when GH and IGF-I levels are discrepant? Clin Endocrinol. 2009;71:166–70.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Holdaway, I.M. (2011). Mortality and Morbidity in Acromegaly: Impact of Disease Control. In: Ho, K. (eds) Growth Hormone Related Diseases and Therapy. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60761-317-6_16
Download citation
DOI: https://doi.org/10.1007/978-1-60761-317-6_16
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-316-9
Online ISBN: 978-1-60761-317-6
eBook Packages: MedicineMedicine (R0)